How do investigators defi ne and modulate circuits in animals that are relevant to the pathophysiology of human neurodegenerative diseases? Animal models provide a variety of advantages for translational investigations related to neurodegenerative diseases, with the best models revealing new understanding of the mechanisms of disease and stimulating new therapeutic interventions. However, animal models have also led to many missteps with investigators following false paths. This review addresses the purpose of these animals models, describes how to identify relevant circuit abnormalities, provides examples of how such models relate to human neurodegenerative diseases, warns of critical limitations of such models, and fi nally suggests that better tools be developed for these translational investigations.
Introduction
How do investigators defi ne and modulate circuits in animals that are relevant to the pathophysiology of human neurodegenerative diseases? To address the series of relevant issues about such animal models and circuits, it is helpful to begin by reviewing the purpose of animal models and what we mean by circuits. Different model systems may be optimal or totally inadequate to address selected research questions, and an investigator must understand the various intricacies that determine the appropriate selection of the right model system. Animal models provide a platform for translational studies that cannot be done safely or as effi ciently in humans. Such models provide a variety of advantages for investigations related to neurodegenerative diseases, with the best models revealing new understanding of the underlying pathophysiology of disease and stimulating development and testing of new therapeutic interventions. In the past, most clinical-anatomic correlation studies focused on specifi c regional defi cits and the corresponding changes in behavior. Recent studies now focus on how such regional defi cits affect brain circuits. In this context, a brain circuit could refer to any linked parts of the brain or perhaps, more appropriately, to a pathway with a start and fi nish that coincide. Of course, the designated "start" or "fi nish" can just be any arbitrary nodes along a pathway; they do not necessarily imply initiation or completion. However, the notion of circuits has extended to networks with recent development of techniques that directly identify or assess the integrity of networks. Thus, studies now commonly investigate changes in brain networks or circuits which underlie normal or abnormal behaviors without obvious isolated focal defects. Animal models have revealed insights into dysfunction of such circuits, but they have also led investigators astray. In this chapter, I review the purpose of defi ning these animals models and describe how relevant circuit abnormalities can be identifi ed. Examples are provided on how such models relate to human neurodegenerative diseases. Critical limitations of such models are discussed and the suggestion is made to develop better tools to permit translational investigations.
Purposes of Animal Models
The selection of an animal model for an investigation requires matching the model system with the research goals. Early animal models focused on identifying biochemical or pharmacologic effects produced by known defects found in human neuropathology. For example, the loss of nigral neurons and subsequent striatal dopamine defi ciency found in brain tissues from people with Parkinson disease (Hornykiewicz and Birkmayer 1961) eventually led to toxininduced models of nigrostriatal dopaminergic neuron injury that mimicked that which occurred in Parkinson disease. Defects in nigrostriatal dopaminergic neurons can be replicated in animals through direct injection, into the relevant brain region, of a neurotoxin (e.g., 6-OHDA) or through direct intracerebral or systemic administration of a protoxin like MPTP or the complex I inhibitor rotenone. Such toxin-induced models have been used to investigate the function of the nigrostriatal pathway and effects of loss of nigral input on basal ganglia circuits, as revealed through changes in glucose metabolism (Wooten and Collins 1981) . The changes in circuits found in such models eventually led to new models of the functional anatomy of basal ganglia circuits (Albin et al. 1989; Mink 1996) .
Similarly, genetic mutations found in humans with neurodegenerative disorders have been used to develop genetic animal models that permit identifi cation of the biochemical consequences of these gene defects. Dramatic advances in genetics have led to the identifi cation of genetic mutations that cause a variety of neurodegenerative disorders, and knowledge of these mutations provides the basis for a host of different types of genetic animal models. This seemingly simple approach is actually far more complex. Genetic models can include knocking out the gene that is defective in humans, knocking in a mutant gene, inducing chromosomal rearrangements, and inserting conditional gene modifi cations (that limit expression of the mutant gene to specifi c brain regions and at selected times). Genetic background also infl uences the effects of specifi c genetic manipulations (Heiman-Patterson et al. 2011 ). Knockouts may demonstrate behaviors unrelated to the specifi c genetic-related behavior in humans with development of other phenotypes, like greater aggressiveness or blindness. Conditional expression of genes can be controlled by the presence or absence of a drug, such as the antibiotic tetracycline through the use of tet/on and tet/off mutations. Tet/on would express the mutation in presence of tetracycline whereas the tet/off would express the mutation in the absence of tetracycline. Knockin models can vary by the degree of expression, which can be even more complicated for modeling triplet repeat disorders (e.g., Huntington disease), in which the number of triplet repeats of CAG can vary from person to person. Thus, different genetic models of Huntington disease with varying numbers of triplet repeats may produce different biochemical consequences, an important issue to keep in mind when interpreting such studies (Pouladi et al. 2012 ). These models may, however, permit related changes in the physiology of pertinent circuits to be identifi ed (Cepeda et al. 2013; Kravitz et al. 2010) . In fact, optogenetic animal models may be useful in teasing out the specifi c function of relevant circuits whose dysfunction contributes to neurodegenerative disorders (Tye et al. 2013) . Many genetic models do not exhibit behaviors that clearly correspond to the human condition, thereby challenging investigators to identify appropriate readouts of pathologic processes. Nevertheless exploration of relevant pathways, identifi cation of cofactors that may contribute to development of pathology, and potential testing of interventions which could interfere with the etiopathology of disease demonstrate some of the incredible translational utilities of these animal models.
Animal models also permit us to test hypotheses about the relationship of known pathologic defects and brain networks. For example, optical imaging has been used to measure cortical network activity in wild-type mice and transgenic mice that exhibit abnormal amyloid beta (A) deposition in brain (histologically visualized as plaques with no measure of soluble A). These studies revealed a correlation between the amount of regional A amyloid deposition (which accompanies Alzheimer disease in humans), changes in functional connectivity, and aging (Bero et al. 2012) . Similarly, people with Huntington disease have loss of medium spiny striatal projection neurons. The consequences of loss of two different types of medium spiny neurons-those inhibited by D2 dopamine receptors or excited by D1 dopamine receptors-have been investigated using animal models with optogenetic approaches that selectively activate one or another of these neuronal populations (Cepeda et al. 2013 ). This type of strategy can reveal changes in networks related to selected genetic defects with subsequent pathological defects relevant not only to Huntington disease but also to normal function of these basal ganglia circuits.
Once identifi ed in animal model systems, pathologic circuits can be used to identify targets for therapeutic interventions or to determine target engagement by selected interventions. A rather straightforward example is the use of the multiple toxin models of nigrostriatal injury which produce behavioral abnormalities that vary in closeness to human Parkinsonism. The conceptual simplicity of such models, however, gives way to varying complexities, depending on the precise model and how it is used. Rodent models have motor behavioral defi cits that have some similarity to human Parkinsonism, whereas nonhuman primate models recapitulate much more closely many of the motor and nonmotor features (Irwin et al. 1990; Tabbal et al. 2012; Brown et al. 2012 Brown et al. , 2013 Schneider et al. 1988 Schneider et al. , 2013 . Levodopa, commonly used to treat Parkinson disease in humans, may ameliorate some of the motor manifestations, but it can also exacerbate nonmotor features in nonhuman primate models, as it may do in human Parkinson disease, further validating this model system (Schneider et al. 2013) . Multiple drugs to treat Parkinsonism were fi rst tested in these animal models based on behavioral responses. In addition, these models can be used to screen other potential therapeutic agents by demonstrating pharmacologic target engagement or change in a measure of severity of brain pathway dysfunction. The key for these studies is to develop and validate appropriate measures (e.g., occupancy of the relevant receptor or changes in activity in a brain circuit). To do this, neuroimaging methods have been used with varying degrees of success. Although specifi c targets can be identifi ed with diverse imaging methods in these models systems, care must be taken to ensure that the measures truly refl ect the underlying pathologic processes; otherwise results obtained can be misleading (Ravina et al. 2005; Karimi et al. 2013; Brown et al. 2013) . The circuit consequences of specifi c defects can be explored with a variety of methods, including MR-based resting state functional connectivity (Helmich et al. 2009; Hacker et al. 2012) , PET-based covariance networks (Ma et al. 2012) , and optogenetic methods (Ozden et al. 2013) . Such changes in networks may provide a means to infer target engagement by a therapeutic agent, as has been suggested for changes in functional connectivity induced by memantine in rodents (Sekar et al. 2013) , as a prelude to potential application to neuropsychiatric conditions. Changes in networks also may be used to investigate the mechanisms of a nonphar- imaging methods can, however, lead to substantial errors in interpreting of the effects of interventions. For example, several studies to test new therapies to slow progression of Parkinson disease employed molecular imaging of presynaptic dopaminergic striatal neurons as a measure of disease severity, since these nigrostriatal dopaminergic neurons degenerate in this disease. In several studies, changes in the striatal uptake of these radioligands seemed to indicate slower progression of the disorder in one group of subjects, whereas clinical measures of progression provided evidence for a more favorable response in the other group (Ravina et al. 2005) . These molecular imaging biomarkers had not been properly validated prior to implementation; that is, no one had determined "standard curves" to demonstrate that these measures truly refl ect changes in severity of loss of nigrostriatal pathways until just recently. We now know that in a model system of toxin-induced damage to the nigrostriatal pathway, all of these striatal measures do not consistently refl ect the severity of injury. Instead, these striatal measures approach zero as nigral cells decrease to 50%, yet motor Parkinsonism continues to progress as more nigral cell bodies die. Thus, previous studies using striatal measures of uptake likely found discordant results with clinical measures since striatal measures of more severely affected individuals were mostly noise (Karimi et al. 2013 ). Thus, validation in animal models prior to application in clinical studies seems prudent. Animal models can also be used to develop and validate biomarkers that can refl ect an underlying pathophysiologic process. The potential value of this type of biomarker is that it can help with diagnosis, if it:
• is found to be suffi ciently specifi c and sensitive, • measures disease severity, • determines target engagement (which in this case refers to appropriate pathway modifi cation) of a therapeutic agent (as discussed above), • provides insight into mechanism of a therapy, or • can be used, with the agreement of regulatory agencies (e.g., the U.S.
Food and Drug Administration or the European Medicines Agency) as a surrogate endpoint for a clinical trial to potentially limit the number of participants needed for such a trial or to shorten the needed length of a trial.
These types of biomarkers frequently must be validated in appropriate animal models that permit careful control of the relevant variables and allow in vitro measures that may not be possible in humans to compare with the biomarkerbased measures. Validation of biomarkers can be tricky and must include welldescribed reproducibility, accuracy, sensitivity, and specifi city for the underlying biologic process. Without these critical steps, biomarker candidates may yield confounding results (Ravina et al. 2005; Karimi et al. 2013 ).
Identifi cation of Circuit Dysfunction Due to Different Defects
A variety of approaches can be employed to defi ne and modulate circuits in animal models that are relevant to the pathophysiology of human neurodegenerative disorders. Circuits or networks of coordinated brain regions can be identifi ed with neuroimaging or electrophysiologic methods. Neuroimaging tools for this include structural imaging that can identify selected patterns of atrophy for specifi c dementing conditions (Kim et al. 2007) , which may stimulate exploration in animal models of spread mechanisms for pathologic proteins (Walker et al. 2013 
Relevance to Neurodegenerative Conditions
These neuroimaging methods have been applied to humans with neurodegenerative conditions and then animal models of these disorders. Surprisingly, some of the standard resting state networks have been found in nonhuman primates or even rodents, despite the fact that the animals were anesthetized at the time of the imaging (Vincent et al. 2007; Mantini et al. 2011) . The effects of anesthesia may not be trivial and remains a major point of investigation; some suggest that light sedation is better than deep anesthesia (Guilfoyle et al. 2013; Kalthoff et al. 2013) . Alternatively, studies can sometimes be performed in awake animals. While this adds a substantial level of complexity and diffi culty, it may prove critical for some types of studies. For example, levodopamediated circuits in nonhuman primates are completely altered by anesthesia (Hershey et al. 2000) . Each neuroimaging method has relatively limited temporal resolution compared to electrophysiologic methods such as MEG, which has poorer spatial resolution but much better temporal resolution (Hall et al. 2013) . In fact, combining different imaging modalities may yield a more complete view of brain networks than any one individual method. For example, it may be possible to combine multiple imaging methods like molecular imaging (with thousandfold greater sensitivity compared to MR methods) with MR-based resting state connectivity, tractography, or both. Similarly, these methods could be combined with electrophysiology, which offers greater temporal resolution. Multimodal studies have been gaining increasing traction and will clearly play a greater role in future studies.
Once seemingly relevant and statistically signifi cant networks have been found in animal models, there are still several criteria that must be met to determine relevance to the human condition. Networks found in animal models that resemble those found in patients with specifi c neurodegenerative disorders suggest that the model may prove to be valid. Next, it would be helpful to know whether changes in the strength of network connectivity relates to a change in the relevant animal behavior. In this way, one could consider using network strength as a biomarker for testing the therapeutic effi cacy of a new proposed intervention. The value of such a biomarker could include greater sensitivity compared to behavioral measures, potentially greater objectivity of the measure, and insight into the underlying mechanism of the intervention. In particular, a biomarker or change in network function that became abnormal prior to behavioral or symptomatic manifestations of a disorder could be particularly helpful in the development of an intervention that could forestall or prevent disease progression, or even the development of any manifestations. It is important to note that an intervention could have substantial behavioral benefi t, even though its mechanism of action could bypass the function of the brain network proposed as a biomarker. A simple example of this would be the application of a molecular imaging of midbrain uptake of radiotracers for nigrostriatal dopaminergic neurons (refl ecting severity of nigrostriatal injury that occurs in Parkinson disease and correlates with severity of motor Parkinsonism) to measure the effi cacy of deep brain stimulation of the subthalamic nucleus (Tabbal et al. 2012; Brown et al. 2013 ). The stimulation effects are downstream of the component of the circuit measured with that particular molecular imaging biomarker (Hershey et al. 2000) . In this case, the network biomarker would not be an appropriate measure of the effi cacy of the intervention, even though it might be used to assess other interventions with different mechanisms of action. Thus, one must approach this type of investigation with caution and have clear goals before selecting the right biomarker.
The key steps in development and validation of a relevant biomarker for use in neurodegenerative diseases require an animal model system. The readout or biomarker applied to such an animal model must be robust, validated, and relevant to either the underlying mechanisms of disease or the behavioral manifestations of the disorder. Validation includes demonstration of a standard curve, just like any assay applied in a lab, especially if the biomarker is to be used to assess therapeutic interventions. To make a standard curve, one needs to be able to produce a graded defi cit in the animal model system and then ensure that the measurement of the biomarker (or in this case, network function) refl ects graded defi cits in a clear manner. Alternatively, a biomarker or change in network function could be intact or not be intact-a categorical designation, potentially important for group classifi cations for research studies. This more limited descriptor still can have value if it is a more sensitive indicator of relevant dysfunction than overt behavior.
Once validated in an animal model system, a biomarker might serve several functions in human studies. If more sensitive than behavioral measures, it could provide an endophenotype for selecting patients for clinical trials (stratifying or enhancing the homogeneity of patient groups) or genetic studies (distinguishing affected from unaffected subjects) (Racette et al. 2006 ). Another strategy is that analysis of various circuit abnormalities can provide sites for target engagement. For example, Bergman et al. (1994) used an MPTP-induced nigrostriatal defi cit in nonhuman primates to identify increased single unit recordings with increased bursting in the internal segment of the globus pallidus. These direct electrophysiologic recordings provided rationale to further pursue pallidotomy and deep brain stimulation of either the subthalamic nucleus (which provides a direct glutamatergic input to globus pallidus) or direct stimulation of globus pallidus for treatment of Parkinson disease (Wichmann et al. 1994 (Wichmann et al. , 1999 . In fact, much of the work on mechanisms of deep brain stimulation has come from studying changes in circuits in animal model systems (Miocinovic et al. 2013) . Investigations using multiple modalities may provide greater insights into the etiopathologic mechanisms of disease than studies which use a single metric of brain function. Examples include investigations of what causes regional vulnerability of selected brain regions to A amyloid pathology, as identifi ed by in vivo amyloid PET imaging in mouse models (Bero et al. 2012 ), or the relationship of various pathophysiologic changes that precede dementia onset in people with dominantly inherited mutation destined to develop the disease (Bateman et al. 2012; Benzinger et al. 2013 ). An important fi nding may be that these brain regions are key components of the default mode network and have high intrinsic brain activity (Sheline et al. 2010 ). Loss of intra-and internetwork resting state functional connectivity may accompany the progression of Alzheimer disease (Brier et al. 2012) . Multimodality studies in animal models of abnormal amyloidosis may permit identifi cation of the key pathologic dysfunctions that lead to these circuit abnormalities; however, these types of studies necessitate an analysis of the underlying changes in brain function, which requires careful in vitro biochemical analyses (Bero et al. 2011 (Bero et al. , 2012 . Thus, the greatest insights into mechanisms of disease may arise from studies that integrate fi ndings from multiple approaches to reveal what biochemical or physiologic processes underlie changes in abnormal brain circuits.
Caveats on Relevance of Animal Model to Human Neurodegenerative Disease
Several caveats must be considered when animal models are implemented to investigate human neurodegenerative disease. As noted, animal behaviors and neuroanatomical complexity frequently require extrapolation to corresponding human behavior or brain circuits. This is less true for nonhuman primates, particularly in neurodegenerative disorders, but clearly applies to rodents, fl ies or zebrafi sh. Imaging studies in animal models frequently employ anesthesia or sedation, which may or may not confound the interpretation of results. Some resting state networks seem relatively impervious to this, but caution is clearly warranted as pharmacologic activation may vary substantially in nonhuman primates, depending on anesthesia (Hershey et al. 2000) . Perhaps, most importantly, the selection of an animal model system must match the goals of an investigation. Some models offer the means to test potential symptomatic treatments (like toxin models), whereas others may be better suited to investigate underlying changes in biochemical pathways (like genetic models). These are not hard and fast rules but rather important guidelines to consider. The development and validation of model systems require an iterative process. Insights from human pathology, physiologic dysfunction, and genetics may provide the initial impetus for development of an animal model and investigation of changes in brain pathways and circuits. However, refi nement of the model almost always yields a better tool. Finally, careful validation of these tools is critical to the interpretation of studies of either the model systems or biomarkers developed using these models. Each investigator that applies such tools needs to be responsible for understanding their advantages and limitations.
What Tools Do We Need?
Genetic models provide useful model systems to investigate underlying brain mechanisms. Advances in genetic engineering based on TALENs and CRISPR (Wang et al. 2013b ) have made development of such models much easier. These studies can be done in mice, faster in zebrafi sh, and even faster in fl ies. However, behavior of animals such as zebrafi sh and fl ies may be diffi cult to align with human behavior, depending upon the complexity of the behavior. Development of sophisticated nonhuman primate genetic models could have a substantial impact on applicability of these model systems. Use of nonhuman primates is likely to be slower and more expensive, but the value and utility of such models may justify the additional effort for some applications (Hutchison and Everling 2012) . Additional work on functional connectivity methods remains to be done. Issues regarding preprocessing these types of data, including potential confounding factors such as the effects of global regression or tolerance for movement during data collection, need further evaluation. Clearer roles for different methods of data analysis will help. Substantial efforts to refi ne functional connectivity with resting state BOLD and anatomical connectivity with tractography through connectome projects offer important opportunities to compare connectivities (Blumensath et al. 2013; Ugurbil et al. 2013) in animal models; some have already started doing direct comparisons between human and nonhuman primates. Application of additional multimodality approaches will help integrate various measures and provide a more complete view of underlying pathology. This represents a particularly critical need, as multimodal approaches can take advantage of the greater sensitivity of molecular imaging, the high spatial resolution of MR-based methods, and the faster temporal resolution of electrophysiology. In addition, further genetic studies in humans with neurodegenerative diseases will help provide genetic mutations upon which to base additional animal models.
The development of biomarkers that measure circuit function or other brain dysfunctions impervious to typical symptomatic treatments would be a major advance for development of interventions that could slow or halt disease progression for conditions like Parkinson disease. This would allow us to test such therapies in patients taking symptomatic therapy and offers two advantages: accuracy of diagnosis frequently increases with longer follow-up and recruitment of treated patients is far easier than recruiting those not yet treated. These advantages translate into substantially lower clinical trial costs. Of course, one must consider whether pathologic progression has exceeded the potential to reverse or slow disease processes at that point. This will depend on the degree of injury that occurs at the time of symptom onset and may vary greatly for different neurodegenerative diseases. Finally, enhanced educational opportunities, improved collaboration between basic investigators and clinician scientists, as well as greater funding for this type of research are all critical if progress is to be exacted. This poses a particular challenge in times of fi nancial constraint.
